Janssen v. Celltrion: Janssen Appeals Judgment Invalidating the ’471 Patent

Approved Biosimilar Products  •  Janssen v. Celltrion (infliximab)  •  U.S. Biosimilar Litigation News  •  U.S. District Court Decisions

As we previously reported, on September 26, 2016, the district court in Janssen v. Celltrion entered partial final judgment that the ’471 patent, asserted by Janssen, was invalid.  Today, Janssen filed a notice that they are appealing the district court’s judgment to the Federal Circuit.

Meanwhile, Celltrion’s partner Pfizer announced last week that it will begin shipping Inflectra® (infliximab-dyyb), their FDA-licensed biosimilar of Remicade®, to wholesalers in late November 2016.  Also, late last week, Celltrion withdrew its motion to dismiss the ’083 patent (i.e., the sole remaining patent in the case) and instead filed a motion for partial summary judgment of non-infringement of that patent.

Stay tuned to the Big Molecule Watch for further updates and analysis.

Download PDF

Comments are closed.